MEDNAX (MD) Misses Q2 EPS by 1c; maintains outlook

MEDNAX (NYSE: MD) reported Q2 EPS of $0.39, $0.01 worse than the analyst estimate of $0.40. Revenue for the quarter came in at $501 million versus the consensus estimate of $495.86 million.

2023 Outlook

As previously disclosed, Pediatrix anticipates that its 2023 Adjusted EBITDA, as defined below, will be in a range of $235 million to $245 million.

For earnings history and earnings-related data on MEDNAX (MD) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• CrowdStrike Holdings Inc. (CRWD) Tops Q1 EPS by 3c, Offers Guidance
• Veeva Systems (VEEV) Tops Q1 EPS by 10c, Offers Guidance